Ask AI

InterACT ADC Treatment Optimization & Care Team Activation in PROC: Enhancing Multidisciplinary Implementation, Toxicity Mitigation, and Workflow Readiness in Community Practice

Explore current evidence and emerging strategies for antibody–drug conjugates in patients with platinum-resistant ovarian cancer, including biomarker-guided use of FRα-directed and HER2-directed therapies and the evolving roles of investigational targets. Examine how biomarker results, prior treatment, rate of disease progression, comorbidities, baseline toxicity risk, patient goals, along with multidisciplinary workflows for treatment readiness and escalation of care.

ADC Optimization in PROC

Activity Information

Released: October 14, 2026